Hyperion Therapeutics completes acquisition of Andromeda Biotech Hyperion Therapeutics announced that it has completed its previously announced acquisition of Andromeda Biotech. The acquisition broadens Hyperion's pipeline to include DiaPep277, a potentially first-in-class immunotherapy for new onset Type 1 diabetes that is currently being evaluated in a fully enrolled confirmatory Phase 3 clinical study in adult patients, with results anticipated in the first quarter of 2015. DiaPep277 holds Orphan Drug designation in the U.S.
News For HPTX From The Last 14 Days
Check below for free stories on HPTX the last two weeks.